Shares of Lipocine (NASDAQ:LPCN) have been assigned an average recommendation of “Buy” from the six ratings firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $12.80.
Several research firms have issued reports on LPCN. Canaccord Genuity restated a “hold” rating and set a $2.00 price target on shares of Lipocine in a report on Tuesday, March 13th. HC Wainwright set a $3.00 price target on shares of Lipocine and gave the stock a “buy” rating in a report on Tuesday, March 13th. Seaport Global Securities assumed coverage on shares of Lipocine in a research note on Thursday, March 29th. They issued a “buy” rating and a $10.00 price objective for the company. Finally, ValuEngine upgraded shares of Lipocine from a “strong sell” rating to a “sell” rating in a research note on Tuesday, May 8th.
Lipocine stock opened at $1.25 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 5.03 and a quick ratio of 5.04. Lipocine has a 52-week low of $1.21 and a 52-week high of $1.26. The company has a market cap of $27.01 million, a price-to-earnings ratio of -1.19 and a beta of 0.52.
Lipocine (NASDAQ:LPCN) last released its quarterly earnings results on Monday, May 7th. The specialty pharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.08. The firm had revenue of $0.43 million for the quarter. analysts forecast that Lipocine will post -0.92 earnings per share for the current year.
An institutional investor recently bought a new position in Lipocine stock. Prosight Management LP acquired a new stake in Lipocine (NASDAQ:LPCN) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 373,101 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,283,000. Lipocine makes up 0.9% of Prosight Management LP’s portfolio, making the stock its 24th biggest holding. Prosight Management LP owned 1.76% of Lipocine at the end of the most recent reporting period. Institutional investors and hedge funds own 17.80% of the company’s stock.
Lipocine Company Profile
Lipocine Inc, a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics, facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability.
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.